011000 — Gene One Life Science Income Statement
0.000.00%
Last trade - 00:00- KR₩178bn
- KR₩204bn
- KR₩36bn
Annual income statement for Gene One Life Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 41,503 | 38,700 | 48,718 | 40,203 | 35,720 |
| Cost of Revenue | |||||
| Gross Profit | 11,412 | 8,757 | 9,336 | -7,759 | -10,868 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 59,396 | 65,117 | 88,768 | 122,258 | 78,759 |
| Operating Profit | -17,893 | -26,416 | -40,050 | -82,055 | -43,039 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -18,226 | -15,534 | -38,054 | -77,655 | -48,753 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18,648 | -15,888 | -38,150 | -77,768 | -48,537 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18,648 | -15,888 | -38,150 | -77,768 | -48,537 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18,648 | -15,888 | -38,150 | -77,768 | -48,537 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -260 | -222 | -493 | -719 | -611 |
| Dividends per Share |